SITE014-0137

SITE014 (NLD) › SITE014-0137

SITE014-0137

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE014 (NLD) · Dr. Moreau
consented 2026-02-13

enrolled

AEs

3

Serious

0

Dropout signal

–

Adverse events

3

Grade 3 Alopecia — outcome: UNKNOWN; onset 2023-02-28 (study day 195); relationship: not assessed

severe assessed

Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-02-11 (study day 178); relationship: NOT RELATED

mild assessed

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-09-09 (study day 23); relationship: NOT RELATED

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.